Introduction
More Americans are surviving cancer today than at any point in recorded medical history. The overall five-year cancer survival rate in the US has climbed from roughly 49% in the 1970s to approximately 69% today — a transformation built on decades of research, earlier detection, and treatment innovations that simply did not exist a generation ago. For millions of patients and families, that statistical shift represents something far more personal than a percentage point: it’s the difference between a funeral and a graduation, a grandchild born, a retirement reached.
But the aggregate number obscures a story of profound inequality — between cancer types, between demographic groups, and between patients who have access to cutting-edge care and those who don’t. Cancer survival rates by type vary from over 99% for localized thyroid cancer to less than 4% for pancreatic cancer diagnosed at a late stage. That is not a small variation. That is the difference between a diagnosis that is scary but manageable and one that reshapes every moment of the time that remains. Understanding cancer survival statistics by type, stage, and demographic is not an academic exercise — it’s the foundation for earlier screening decisions, smarter treatment conversations, and more honest public health policy.
In 2026, the cancer survival rate landscape is being reshaped by immunotherapy breakthroughs, liquid biopsy early detection tools, AI-assisted pathology, and an expanding roster of targeted therapies that treat tumors by their molecular signature rather than their organ of origin. This article covers the latest survival rate data for the most common and deadliest cancer types, breaks down how survival varies by stage, age, and race, and explains what the numbers mean for patients facing a new diagnosis today.
Cancer Survival Rate Statistics by Type – Quick Facts Table
| Key Fact | Latest Data (US 2026) |
|---|---|
| Overall 5-year cancer survival rate (all types combined) | ~69% |
| New cancer cases diagnosed annually in the US | ~2.0 million |
| Cancer deaths annually in the US | ~611,000 |
| Cancer type with highest 5-year survival rate | Thyroid cancer (~98%) |
| Cancer type with lowest 5-year survival rate | Pancreatic cancer (~13%) |
| Most commonly diagnosed cancer (excluding skin) | Breast cancer |
| Leading cause of cancer death (men) | Lung cancer |
| Leading cause of cancer death (women) | Lung cancer |
| Improvement in overall survival rate since 1991 | ~33% reduction in cancer death rate |
| Adults who are cancer survivors in the US | ~18.1 million |
Source: American Cancer Society, National Cancer Institute SEER Database, CDC Cancer Statistics, ASCO (2024–2026 reports)
Table of Contents
- What Are Cancer Survival Rates?
- Cancer Survival Rates by Type in the US 2026
- Cancer Survival Rates by Stage in the US 2026
- Cancer Survival Rates by Demographics in the US 2026
- Most Deadly Cancers in the US 2026
- Comparison Table: Most Survivable vs. Least Survivable Cancers
- Trends and Insights for 2026
- FAQs
What Are Cancer Survival Rates?
Cancer survival rates measure the percentage of people diagnosed with a specific cancer who are still alive after a defined period — most commonly five years from diagnosis. The five-year survival rate is the standard benchmark used by oncologists, researchers, and public health agencies because it provides a consistent, comparable metric across cancer types and time periods. It does not mean a patient is cured at five years, nor does it mean someone who passes the five-year mark is out of danger — it is a statistical snapshot of a population’s outcomes, not a personal prediction.
There are several ways survival rates are reported, and the distinctions matter. Relative survival rate compares cancer patients to the general population of similar age and sex, adjusting for deaths from other causes. Disease-specific survival rate counts only deaths from that cancer. Overall survival rate counts all deaths regardless of cause. When reading cancer survival statistics, checking which definition is being used is essential — a 90% relative survival rate tells a very different story than a 90% overall survival rate for an older population with multiple health conditions. All figures in this article use five-year relative survival rates unless otherwise noted, consistent with NCI SEER database reporting standards.
Cancer Survival Rates by Type in the US 2026
| Cancer Type | 5-Year Relative Survival Rate | Annual New Cases (est.) | Annual Deaths (est.) |
|---|---|---|---|
| Thyroid | ~98% | ~44,000 | ~2,200 |
| Testicular | ~95% | ~9,900 | ~470 |
| Melanoma (skin) | ~94% | ~100,640 | ~8,290 |
| Breast (female) | ~91% | ~313,510 | ~42,780 |
| Prostate | ~97% | ~299,010 | ~35,250 |
| Cervical | ~67% | ~13,820 | ~4,360 |
| Non-Hodgkin lymphoma | ~74% | ~80,620 | ~20,140 |
| Leukemia (all types) | ~67% | ~59,610 | ~23,660 |
| Kidney (renal cell) | ~77% | ~81,610 | ~14,990 |
| Colorectal | ~65% | ~154,270 | ~52,900 |
| Ovarian | ~49% | ~19,680 | ~12,740 |
| Lung & bronchus | ~26% | ~234,580 | ~125,070 |
| Liver (hepatocellular) | ~22% | ~41,630 | ~29,840 |
| Esophageal | ~22% | ~22,370 | ~16,130 |
| Pancreatic | ~13% | ~66,440 | ~51,750 |
| Glioblastoma (brain) | ~7% | ~14,490 | ~10,012 |
The spread across cancer types in this table is the central fact of oncology that the public most needs to understand. Thyroid cancer at ~98% and prostate cancer at ~97% are, for most patients, survivable diseases — serious, life-altering in the short term, but unlikely to be fatal with appropriate treatment. Pancreatic cancer at ~13% and glioblastoma at ~7% occupy an entirely different medical reality, one where the honest conversation between oncologist and patient sounds very different from the outset.
What drives this variation? The dominant factors are how early the cancer is typically detected and how effectively current treatments work against that tumor biology. Thyroid and prostate cancers are often caught in localized stages before spread occurs, and they respond well to surgery, radiation, or active surveillance. Pancreatic and glioblastoma cancers, by contrast, produce few symptoms until they have spread extensively, and their tumor biology makes them resistant to most available therapies. Improving survival rates for the deadliest cancers requires solving both problems simultaneously — earlier detection tools and better treatments — which is exactly where the most intensive research investment is concentrated in 2026.
Cancer Survival Rates by Stage in the US 2026
| Cancer Type | Localized (Stage I) | Regional (Stage II–III) | Distant (Stage IV) |
|---|---|---|---|
| Breast (female) | ~99% | ~86% | ~31% |
| Prostate | ~99% | ~99% | ~34% |
| Colorectal | ~91% | ~73% | ~15% |
| Lung & bronchus | ~63% | ~35% | ~8% |
| Melanoma | ~99% | ~71% | ~35% |
| Ovarian | ~92% | ~72% | ~31% |
| Pancreatic | ~44% | ~15% | ~3% |
| Cervical | ~91% | ~60% | ~19% |
| Kidney | ~93% | ~71% | ~16% |
| Bladder | ~96% | ~38% | ~8% |
Stage at diagnosis is the single most powerful predictor of cancer survival — more than the treatment center, more than the specific drug protocol, and in many cases more than the specific cancer type. Localized breast cancer carries a ~99% five-year survival rate; that same breast cancer caught after metastasizing to distant organs drops to ~31%. Ovarian cancer, which is frequently diagnosed late because early-stage disease produces vague or no symptoms, shows an especially stark divide: ~92% survival when localized vs. ~31% when distant — a gap that underscores why research into early detection for ovarian cancer has become a top-priority area.
The lung cancer staging data deserves special attention because it illustrates both the stakes of early detection and the scale of the problem. Lung cancer caught at a localized stage is survivable — ~63% five-year survival — yet only roughly 28% of lung cancers are diagnosed at this stage, because the disease is largely asymptomatic until it has spread. Low-dose CT screening for high-risk individuals (current or former heavy smokers aged 50–80) is now strongly recommended by the USPSTF and can meaningfully shift that diagnostic distribution — but screening uptake remains stubbornly low, with fewer than 10% of eligible Americans completing annual lung cancer screening.
Cancer Survival Rates by Demographics in the US 2026
| Demographic Factor | Group | 5-Year Relative Survival (All Cancers) |
|---|---|---|
| Sex | Male | ~67% |
| Sex | Female | ~71% |
| Race | White | ~70% |
| Race | Black / African American | ~64% |
| Race | Hispanic / Latino | ~68% |
| Race | Asian American | ~74% |
| Race | American Indian / Alaska Native | ~59% |
| Age at diagnosis | Under 45 | ~83% |
| Age at diagnosis | 45–64 | ~71% |
| Age at diagnosis | 65–74 | ~66% |
| Age at diagnosis | 75+ | ~55% |
| Insurance status | Insured | ~72% |
| Insurance status | Uninsured | ~58% |
The demographic disparities in cancer survival rates are among the most persistent and troubling findings in American oncology. Black Americans have a five-year survival rate approximately 6 percentage points lower than white Americans across all cancer types combined — a gap that has narrowed since the 1990s but has not closed. The causes are well-documented: later-stage diagnoses driven by reduced access to screening, lower rates of insurance coverage, geographic concentration in areas with fewer specialized cancer centers, higher rates of certain aggressive cancer subtypes, and documented disparities in treatment intensity and clinical trial enrollment.
The insurance status data is perhaps the most policy-actionable finding in this table. Insured patients survive cancer at rates roughly 14 percentage points higher than uninsured patients — a gap larger than the difference between many cancer types. This is not primarily a biological difference. It reflects the fact that uninsured patients are more likely to delay seeking care, less likely to receive guideline-concordant treatment, and more likely to be diagnosed at a distant stage when curative treatment is no longer possible. Access to insurance is, in measurable and statistically significant terms, a cancer survival intervention.
Most Deadly Cancers in the US 2026
| Cancer Type | Annual Deaths | 5-Year Survival Rate | Median Age at Diagnosis | Primary Risk Factor |
|---|---|---|---|---|
| Lung & bronchus | ~125,070 | ~26% | 70 | Smoking, radon, air pollution |
| Colorectal | ~52,900 | ~65% | 66 | Diet, sedentary lifestyle, genetics |
| Pancreatic | ~51,750 | ~13% | 71 | Smoking, obesity, diabetes |
| Breast (female) | ~42,780 | ~91% | 62 | Genetics, hormones, lifestyle |
| Prostate | ~35,250 | ~97% | 67 | Age, race, family history |
| Liver & bile duct | ~29,840 | ~22% | 64 | Hepatitis B/C, alcohol, obesity |
| Leukemia | ~23,660 | ~67% | 67 | Radiation, chemicals, genetics |
| Non-Hodgkin lymphoma | ~20,140 | ~74% | 67 | Immune suppression, infections |
| Brain & CNS | ~18,990 | ~36% | 59 | Unknown (largely) |
| Esophageal | ~16,130 | ~22% | 68 | Reflux, smoking, obesity |
This table reveals a counterintuitive but important truth: death toll and survival rate are separate dimensions. Breast cancer kills over 42,000 Americans annually despite a ~91% survival rate — because it is so common that even a small percentage of fatal cases generates enormous absolute numbers. Pancreatic cancer, with its devastating ~13% survival rate, kills nearly as many people per year as breast cancer but from a fraction of the diagnoses. Both facts matter, and conflating death counts with survival rates leads to misallocated fear, misallocated research funding, and poorly calibrated screening behavior.
Lung cancer remains the undisputed leading cause of cancer death in both men and women, killing more Americans annually than colorectal, breast, and prostate cancers combined. Despite this, public awareness campaigns, research funding per death, and screening participation rates for lung cancer remain disproportionately low relative to its lethal burden. The low-dose CT screening recommendation for high-risk adults is one of the most evidence-backed interventions in all of preventive medicine — and yet one of the most underutilized. Closing that gap alone could prevent tens of thousands of deaths annually.
Comparison Table: Most Survivable vs. Least Survivable Cancers
| Factor | Most Survivable Cancers | Least Survivable Cancers |
|---|---|---|
| Examples | Thyroid, testicular, melanoma (local), prostate | Pancreatic, glioblastoma, esophageal, liver |
| Average 5-year survival rate | ~90–98% | ~7–22% |
| Typical stage at diagnosis | Mostly localized | Mostly regional or distant |
| Effective screening tools available | Yes (most) | Limited or none |
| Response to standard treatment | Generally strong | Generally poor |
| Treatment options | Surgery, radiation, targeted therapy | Limited; clinical trials often best option |
| Survival improvement since 1990 | Significant (+15–30%) | Modest (+3–8%) |
| Research investment trend | Moderate | Rapidly increasing |
| Median age at diagnosis | 50–65 | 64–71 |
| Geographic survival variance (US) | Moderate | High |
The contrast between the most and least survivable cancers is not simply a story of medical luck — it is substantially a story of biological detectability and treatment responsiveness. The most survivable cancers tend to grow slowly, produce early symptoms or are caught by established screening programs, and respond to a broad range of treatments. The least survivable cancers tend to grow aggressively, produce no early warning signs, and harbor molecular resistance mechanisms that make standard chemotherapy and even newer targeted agents minimally effective.
The survival improvement figures since 1990 may be the most instructive row in this table. For highly survivable cancers, improvements have been significant because researchers had a productive foundation to build on. For the deadliest cancers — pancreatic, glioblastoma, esophageal — the gains over three decades have been modest at best, reflecting how fundamentally difficult these tumors are to treat once established. This is precisely why the research community’s increasing focus on early detection technologies — liquid biopsy blood tests capable of detecting multiple cancers from a single blood draw — represents potentially the most transformative shift in oncology since chemotherapy.
Trends and Insights for 2026
The cancer survival rate landscape in 2026 is defined by genuine scientific progress colliding with persistent systemic inequity. Here are the most significant data-backed developments:
- Overall cancer death rates continue to fall. The US cancer death rate has dropped approximately 33% since its 1991 peak, and the decline is accelerating. The American Cancer Society estimates this translates to roughly 4.1 million deaths averted compared to what would have occurred at peak rates — one of the most significant public health achievements of the modern era.
- Immunotherapy is rewriting survival curves. Checkpoint inhibitor drugs — which unleash the immune system against tumor cells — have produced durable long-term remissions in cancers previously considered uniformly fatal, including certain lung cancer subtypes, advanced melanoma, and some head and neck cancers. Roughly 10–15% of cancer patients now receive some form of immunotherapy, and that share is expanding rapidly.
- Multi-cancer early detection (MCED) tests are approaching mainstream clinical use. Blood-based liquid biopsy tests capable of detecting 50+ cancer types from a single draw are moving through large clinical trials in 2025–2026. If validated, they could fundamentally shift the stage-at-diagnosis distribution across the deadliest cancer types — the single intervention most likely to improve survival for pancreatic, ovarian, and lung cancers in the near term.
- Racial survival gaps are narrowing — but not fast enough. The Black-white cancer survival gap has shrunk by roughly one-third since 2000, primarily due to improvements in colorectal cancer screening access and breast cancer treatment equity initiatives. But the remaining gap — approximately 6 percentage points overall — represents tens of thousands of preventable deaths annually and reflects structural barriers that require structural solutions.
- Obesity-related cancer incidence is rising in younger adults. Cancers historically rare in people under 50 — including colorectal, endometrial, kidney, and pancreatic cancers — are increasing in younger age groups at rates that researchers directly attribute to rising obesity rates. The American Cancer Society moved its colorectal screening recommendation from age 50 to age 45 in response.
- Survivorship care is a growing gap. With 18.1 million cancer survivors in the US — a number projected to exceed 22 million by 2030 — the healthcare system is struggling to provide adequate long-term follow-up care for the physical, psychological, and financial consequences of cancer and its treatment. Survivorship care plans are recommended for all patients completing treatment but are provided to fewer than half of eligible survivors.
- AI in pathology and radiology is accelerating. Machine learning tools trained on millions of cancer images are now demonstrating diagnostic accuracy matching or exceeding specialist physicians for certain cancer types in controlled studies. Early deployment in screening mammography and lung CT interpretation is reducing both false positives and missed diagnoses — improving the quality of detection that feeds into survival statistics.
FAQs
1. What is the overall cancer survival rate in the US?
The overall five-year relative survival rate for cancer in the US is approximately 69% as of 2026 data, meaning roughly 69 out of every 100 Americans diagnosed with cancer survive at least five years relative to people of similar age without cancer. This figure represents a dramatic improvement from the 49% rate recorded in the early 1970s and reflects decades of advances in early detection, surgical techniques, radiation precision, targeted therapy, and immunotherapy. It’s important to note that this is an aggregate across all cancer types and stages — individual prognosis depends heavily on the specific cancer type, stage at diagnosis, treatment received, and patient-specific biology.
2. Which cancer has the highest survival rate?
Thyroid cancer holds the highest five-year relative survival rate of any major cancer at approximately ~98% overall. When caught at a localized stage — which describes the majority of thyroid cancer diagnoses — survival approaches ~99.5%. Testicular cancer is a close second at ~95% overall, with localized cases exceeding 99%. Prostate cancer also carries a ~97% overall survival rate, though it’s worth noting this reflects the high proportion of slow-growing, localized prostate cancers that may never become life-threatening regardless of treatment. These high survival rates reflect both the biological behavior of these tumors and the effectiveness of established treatment protocols.
3. Which cancer has the lowest survival rate?
Glioblastoma (the most aggressive form of brain cancer) carries the lowest five-year survival rate of any common cancer at approximately ~7%, followed closely by pancreatic cancer at ~13%. For pancreatic cancer diagnosed at the most advanced (distant) stage — which describes roughly 50% of cases at diagnosis — the five-year survival rate falls to approximately ~3%. These devastating statistics reflect two compounding problems: both cancers are almost never detected early (when survival is meaningfully better), and both tumors harbor biological features that make them resistant to most currently available treatments, including many newer targeted therapies and immunotherapy agents.
4. How do cancer survival rates differ by stage?
Stage at diagnosis is the most powerful determinant of cancer survival — often more impactful than the cancer type itself. Localized cancers (confined to the original site) carry average five-year survival rates above 90% for many types. Regional cancers (spread to nearby lymph nodes or tissue) typically see survival rates in the 50–85% range. Distant or metastatic cancers (spread to remote organs) often carry survival rates below 30% — and for the most aggressive cancer types, single-digit survival rates at the distant stage. This is why cancer screening recommendations exist: catching cancer one stage earlier is not just a statistical improvement, it is often the difference between a curative and a palliative treatment approach.
5. Why do Black Americans have lower cancer survival rates?
Black Americans have a five-year cancer survival rate approximately 6 percentage points lower than white Americans, a disparity that persists across most cancer types and cannot be fully explained by biology. The primary drivers are structural and systemic: later-stage diagnosis resulting from reduced access to routine screening and primary care; lower rates of insurance coverage leading to delayed treatment; geographic concentration in areas with fewer specialized cancer centers and oncology specialists; documented disparities in receipt of guideline-recommended treatments; and underrepresentation in clinical trials that provide access to cutting-edge therapies. The gap is narrowing — colorectal and breast cancer disparities have improved meaningfully — but closing it entirely requires addressing underlying healthcare access inequities, not just improving cancer treatments.
6. What does a 5-year survival rate actually mean for an individual patient?
A five-year survival rate tells you what percentage of a large group of patients with that specific cancer diagnosis were alive five years after diagnosis — it does not predict what will happen to any individual. A 70% five-year survival rate does not mean a specific patient has a 70% chance of surviving — it means 70 out of 100 people in a historical dataset with similar diagnoses were alive at five years. Individual outcomes depend on dozens of factors that population statistics can’t capture: specific tumor mutations, overall health status, treatment response, access to care, and biological factors not yet fully understood. Survival statistics are useful for understanding the landscape of a diagnosis — they are a starting point for conversation, not a verdict.
7. How has cancer survival improved over the past 30 years?
Cancer survival in the US has improved dramatically since the early 1990s, when the overall five-year survival rate was approximately 50% and the cancer death rate was at its all-time peak. Since 1991, the overall cancer death rate has fallen by approximately 33%, translating to an estimated 4.1 million averted deaths. The improvements have been driven by a combination of reduced smoking rates (lowering lung cancer incidence and death), widespread adoption of colorectal, breast, and cervical cancer screening programs, more effective chemotherapy regimens, the emergence of targeted therapies for specific molecular subtypes, and the immunotherapy revolution beginning in the 2010s. Progress has been uneven — pancreatic and glioblastoma survival has barely moved — but the aggregate trend is one of genuine, sustained progress.
8. What new treatments are improving cancer survival rates in 2026?
Several treatment categories are meaningfully shifting cancer survival statistics in 2026. Checkpoint immunotherapy (PD-1/PD-L1 inhibitors) has produced durable, long-term remissions in advanced melanoma, non-small cell lung cancer, bladder cancer, and several other types — outcomes that were essentially unheard of a decade ago. CAR-T cell therapy is achieving complete remissions in certain blood cancers that had exhausted all other options. Antibody-drug conjugates (ADCs) are delivering chemotherapy payloads directly to tumor cells with increasing precision, improving efficacy while reducing systemic toxicity. Targeted therapies matched to specific tumor gene mutations — EGFR, ALK, BRCA, HER2, and many others — are converting certain metastatic diagnoses from uniformly fatal to chronic, manageable conditions for subsets of patients with matching tumor profiles.
Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.